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Abstract
The Cancer Genome Atlas project has generated multi-dimensional and highly integrated genomic data from a large number
of patient samples with detailed clinical records across many cancer types, but it remains unclear how to best integrate the
massive amount of genomic data into clinical practice. We report here our methodology to build a multi-dimensional subnet-
work atlas for cancer prognosis to better investigate the potential impact of multiple genetic and epigenetic (gene expression,
copy number variation, microRNA expression and DNA methylation) changes on the molecular states of networks that in turn
affects complex cancer survivorship. We uncover an average of 38 novel subnetworks in the protein–protein interaction net-
work that correlate with prognosis across four prominent cancer types. The clinical utility of these subnetwork biomarkers
was further evaluated by prognostic impact evaluation, functional enrichment analysis, drug target annotation, tumor stratifi-
cation and independent validation. Some pathways including the dynactin, cohesion and pyruvate dehydrogenase-related
subnetworks are identified as promising new targets for therapy in specific cancer types. In conclusion, this integrative ana-
lysis of existing protein interactome and cancer genomics data allows us to systematically dissect the molecular mechanisms
that underlie unexpected outcomes for cancer, which could be used to better understand and predict clinical outcomes, opti-
mize treatment and to provide new opportunities for developing therapeutics related to the subnetworks identified.
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Introduction
Cancer is a complex disease arising from the combined effects
of multiple genetic and epigenetic changes, leading to the dys-
regulation of critical signaling pathways [1–5]. Owing to recent
advances in next-generation sequencing technology and its
emerging application in various clinical settings, it is now pos-
sible to evaluate cancers beyond the traditional clinical vari-
ables (i.e. age and tumor stage) by incorporating data profiled
on multiple layers of genomic activities, such as gene expres-
sion profiles, genetic aberrations [somatic mutations and copy
number variants (CNVs)], microRNA (miRNA) expression and
methylation signatures. These additions in tumor profiling and
stratification further improve the predictions in prognosis and
outcomes [6].
Highly integrated analyses using multi-layered molecular in-
formation to help understand cancer outcomes have also been
demonstrated [7–13]. Study by Xu et al. [7] showed that some as-
sociations between DNA copy number and gene expression
have clinical or pathogenic relevance. Masica and Karchin [8]
identified genes required for tumor’s survival by examining the
correlations among somatic mutation and gene expression.
Kim et al. [9] integrated information from miRNA and mRNA ex-
pression profiles to improve the prediction of cancer survival
time. Kim et al. [10] experimentally revealed an oncomir/onco-
gene cluster through integrative genome analysis, which could
regulate glioblastoma survivorship by targeting RB1, PI3K/AKT
and JNK pathways. Meanwhile, more studies started to include
both genetic and epigenetic alterations in tumors in decision-
making processes in clinical practice. For example, Zhang et al.
[13] uncovered seven previously uncategorized subtypes of
ovarian cancer that differentiate significantly in median sur-
vival time by integrating four types of molecular data related to
gene expression. In light of these pioneering computational and
experimental works, we seek to explore the cooperative effect
of multi-layered genetic and epigenetic regulatory mechanisms.
Moreover, recent studies have focused on how multiple
genes interact in a particular pathway or network to explain a
complex clinical outcome [14–17]. For example, human protein–
protein interaction (PPI) networks have been used to identify
subnetwork signatures or functional modules that contribute to
the positive or negative prognosis of glioblastoma multiforme
(GBM), breast, colon, rectal, as well as ovarian cancers [14, 18],
and the regulatory relationships of miRNAs and their target
genes have been used in survival analysis of GBM and ovarian
cancer [16]. A priori defined gene sets from MSigDB or KEGG
pathway have also been associated with patient survival in
breast cancer [15] and serious ovarian cancer [17].
The Cancer Genome Atlas (TCGA) project has provided re-
sources for multi-platform genomic profiling from a large num-
ber of patient samples across many cancer types [1–4], resulting
in multi-dimensional and highly integrated genomic data.
Combined with improvements in the quality of interactome
data, network analysis has made significant advancements in
cancer biology. However, how to translate such multi-omics
data into clinical application is still challenging. In this work,
we propose a systematic approach to (i) evaluate the contribu-
tion of genes to patient survival taking into account
multi-layered regulatory mechanisms including CNV, DNA
methylation, mRNA and miRNA expression; (ii) identify
subnetworks of the survival-related genes in PPI network; (iii)
and generate multi-dimensional subnetwork-derived prognos-
tic models. Finally, we uncover an average of 38 new featured
subnetworks linked with prognosis across four cancer types.
Further functional enrichment analysis, drug target annotation,
tumor stratification and independent validation were used to
evaluate the clinical utility of these subnetwork-derived models
in cancer prognosis. Our study demonstrates a novel method
for integrating human genomics and interactome data that
proves useful for refining our biological understanding of cancer
prognosis and potentially improving outcomes.
Material and methods
Study design
The aim of our study was to detect the potential impact of mul-
tiple genetic and epigenetic changes on the molecular states of
networks that in turn affects complex cancer outcome. We
reported the methodology to build a multi-dimensional subnet-
work atlas for cancer prognosis through integrating the multi-
type cancer genomics data from 1027 samples of four cancer
types from TCGA project and the interactome data including PPI
and miRNA–gene interaction. We further assessed the clinical
utility of these multi-dimensional subnetwork biomarkers
through prognostic impact evaluation, functional enrichment
analysis, drug target annotation, tumor stratification and inde-
pendent validation.
Multi-dimensional genomic data
The multi-dimensional cancer-associated data sets containing
clinical information, copy-number variation (CNV), promoter
DNA methylation, mRNA-gene and miRNA expression data
were collected from TCGA Cancer Browser (https://genome-can
cer.ucsc.edu/proj/site/hgHeatmap/). A brief summary of the
data information is provided in Table 1. Overall survival data of
patients in four TCGA cancer types were considered in our art-
icle: lung squamous cell carcinoma (LUSC), GBM, kidney renal
clear cell carcinoma (KIRC) and ovarian serous cystadenocarci-
noma (OV).
Protein–protein interaction data
The PPIs data from Human Protein Reference Database (HPRD)
[19] were used in this study. HPRD contains over 36 700 manu-
ally curated interactions between 9205 human proteins.
Identification of the miRNA-regulators for target genes
Two miRNA target databases (miRTarBase (Release 4.5) [20] and
TarBase v6 [21]), which provide experimentally validated
miRNA–target interactions, were used. Because the biologically
relevant targets of each miRNA may vary from one tissue to the
next, depending on the expression of the target mRNAs and the
cellular context, we selected those miRNAs whose expression
was inversely correlated (r<0.15, P < 0.01), with mRNA ex-
pression in each cancer type as the regulators for the target
genes [10].
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Data processing
We downloaded a list of expressed genes from syn1734155,
including 12 081 genes with at least 3 RNA-Seq reads per sample
in at least 70% of samples. We restricted the downstream ana-
lysis to these shared genes plus 18 well-known cancer genes
(AR, CDH4, EGFR, EPHA3, ERBB4, FGFR2, FLT3, FOXA1, FOXA2,
MECOM, MIR142, MSH4, PDGFRA, SOX1, SOX9, SOX17, TBX3, WT1)
that have low-transcript detection levels, as used in [22]. As
such, 12 099 genes were considered in total.
CNV profiling was estimated using the GISTIC2 method,
annotated to genes using UCSC cgData HUGO probeMap, and
further filtered with 12 099 expressed genes. Finally, CNV of
11 878 genes was consolidated in 468 LUSC, 420 GBM, 517 KIRC
and 559 OV samples.
The DNA methylation profile was measured experimentally
either using the Illumina Infinium Human DNA Methylation
450K (for LUSC and KIRC) or 27K (for GBM and OV) platform.
After filtering out all probes with missing values in the DNA
methylation profile, the probes were mapped onto the human
genome coordinates using cgData probeMap derived from GEO
GPL13534 record and further filtered with the selected 12 099 ex-
pressed genes. In all, we mapped 197 569 probes to 11 350 genes
in 341 LUSC samples, 14 445 probes to 8966 genes in 214 GBM
samples, 197 940 probes to 11 355 genes in 309 KIRC samples
and 13 628 probes to 8790 genes in 579 OV samples.
The mRNA expression profile was measured using either
Agilent 244K Custom Gene Expression G4502A (for GBM) or
Illumina HiSeq 2000 RNA Sequencing V2 (for LUSC, KIRC and
OV). Finally, there were 11 442 genes used both in 467 LUSC and
522 KIRC samples, 10 097 genes in 348 GBM samples and 11 479
genes in 414 OV samples.
The miRNA expression profile was measured experimentally
using the Illumina HiSeq 2000 RNA Sequencing platform.
miRNAs that were expressed in less than five patients were
removed. In the end, there were 794, 716 and 673 miRNAs used
in LUSC, KIRC and OV, respectively.
For each cancer type, we defined the sample intersection
across all platforms as the core sample set.
Identification of novel subnetwork signatures of
survival-related genes
For each gene, we evaluated its effect on the survival time of pa-
tients by taking into account all four types of molecular features
(mRNA expression, CNV, promoter DNA methylation status and
the expression of its regulatory miRNA). The R program ‘coxph’
was used to fit a univariate Cox proportional hazards model be-
tween each molecular feature and patient survival time, with
the likelihood ratio test being used to estimate the significance.
Only the features that passed the cutoff of P < 0.05 were
considered to be related to survival time. From this analysis, we
derived a score (heat) for each gene calculated through the
Equation (1), which was summarized as the sum negative nat-
ural logarithm of single molecular feature P-values (Figure 1A).
This sum corresponded to the statistic of Fisher’s Method for
combining P-values for (independent) statistical tests [23] and





logeðpmÞ;m ¼ mRNA;CNV;methy;miRNA (1)
For mRNA-gene expression or CNV, P value was defined as:
pm ¼
(
p; p < 0:05
1; p  0:05
;m ¼ mRNA;CNV (2)
For miRNA expression or DNA methylation, considering the
fact that one gene may have multiple methylation loci or sev-
eral miRNA regulators, we only retained one CpG methylation
probe or one of its miRNA regulators that was most correlated
with survival time, and the P value was defined as:
pm ¼
(
minðpÞ; minðpÞ < 0:05
1; minðpÞ  0:05
;m ¼ methy;miRNA (3)
The genes with a score> 0 were identified as survival-
related genes. Then, the heat score was used as the input into
HotNet2 [22, 23], which uses a heat diffusion process and a stat-
istical test-based algorithm to discover subnetwork signatures
in PPI network (Figure 1B). Thus, subnetwork signatures of
survival-related genes were determined both by the scores of
their genes and the interactions between the genes.
Training and evaluation of multi-dimensional subnet-
work-derived prognostic models
For each subnetwork, we first assembled a multi-dimensional
molecular profile by extracting all four types of molecular fea-
tures of its gene members from the core sample set of a particu-
lar cancer type. We then explored the predictive power of the
subnetwork on patient overall survival using a Monte Carlo
cross-validation and permutation testing procedure. Briefly, for
the core sample set, we randomly split the samples into two
groups: 80% as the training set and 20% as the test set. To fairly
and accurately evaluate the prognostic power of each subnet-
work (with different number of genes), on the training set, we
used the Cox proportional hazards model with L1 penalized log
partial likelihood (LASSO) [24] for feature selection to train the
models based on the molecular profile of individual
Table 1. Summary of specimens derived from TCGA by high-throughput analysis of the four primary molecular features for each cancer type
Cancer CNV Methylation mRNA miRNA Core set
LUSC GISTIC2 450k HiseqV2 HiSeq
468  11 878 genes 341  197 569 probes 467  11 442 genes 316  794 miRNAs 313
GBM GISTIC2 27k AgilentG4502A Not used
420  11 878 genes 214  14 445 probes 348  10 097 genes 156
KIRC GISTIC2 450k HiseqV2 HiSeq
517  11 878 genes 309  197 940 probes 522  11 442 genes 244  716 miRNAs 169
OV GISTIC2 27k HiseqV2 HiSeq
559  11 878 genes 579  13 628 probes 414  11 479 genes 487  673 miRNAs 398
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subnetwork. The prognostic outcomes for the training set were
used to determine the regression coefficients. These coefficients
were then used to predict outcomes for patients in the test set
and calculate the concordance index (C-index). The above pro-
cedure was repeated 100 times to generate 100 C-indexes, and
the median C-index was used as the predictive value for each
subnetwork (Figure 1C). Furthermore, to test if the models built
from each subnetwork showed statistically significant predict-
ive power, 100 survival-permuted data were used to calculate P-
values based on the comparison of the median C-index values
of the original survival data with the distributions of the median
C-indexes of the 100 survival-permuted data. Our survival pre-
dictive models were evaluated based on a research framework,
which could be accessed in Synapse (doi:10.7303/syn1710282).
Accordingly, to assess the predictive power of integrating mo-
lecular data with clinical variables, we combined the molecular
features with clinical variables to build a new multivariate Cox
model. To compare the performance across different prognostic
models, the one-tailed Wilcoxon signed rank test was used to cal-
culate the P-value (P< 0.05 as the significance cutoff).
Figure 1. An overview of the computational approach. (A) A score (heat) was derived for each gene to evaluate the collaborative effect of different molecular features
(gene expression, CNV, miRNA expression and DNA methylation) on patient survival time. First, P-values representing the significance of each molecular feature corre-
lated with patient overall survival time were calculated using the likelihood ratio test of univariate cox model. The score was then calculated as the negative sum of
the natural logarithm of the single molecular feature P-values (Red: high score; Yellow: low score; White: score¼0). (B) Subnetworks were identified using HotNet2 algo-
rithm in a PPI network. HotNet2 used a heat diffusion process and a statistical test to derive significant subnetworks based on both the score of the genes and the local
topology of the subnetwork. (C) Monte Carlo cross-validation and the concordance index (C-index) were applied to assess the predictive power of each subnetwork sig-
nature, based on either the multi-dimensional genomics data alone (blue) or in combination with clinical variables (red).
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Selection and characterization of important molecular
features in the prognostic models
When building the predictive model using the molecular fea-
tures of each subnetwork, LASSO was used to select a small
number of ‘important’ features. Basically, 100 samplings of the
training set could extract 100 important feature sets and the oc-
currence of each molecular feature was counted (Figure 3A).
Because the possibility of random selection bias for any given
feature could be ruled out if the feature was consistently se-
lected for, we only kept features occurring more than five times
to construct our final predictive model. The selected features
were fitted in a multivariable Cox regression model using all the
samples. A risk score formula was then established by weight-
ing each of these selected features by their estimated regression
coefficients in the multivariable Cox regression analysis. With
this risk score formula, patients in each set were classified into
high-risk or low-risk groups using the median risk score as the
cutoff. Survival differences between the low-risk and high-risk
groups identified in each set were assessed by the Kaplan–Meier
estimate and compared using the log-rank test. Z-score trans-
formation was used to adjust the data scale among different
molecular data sets when generating heatmaps.
Results
Collaborative effect of genetic or epigenetic molecular
features on cancer patient survival
We first investigated how multiple layers of cellular activities
(either genetic or epigenetic) may contribute to clinical out-
comes (i.e. patient survival time) in different cancer types. From
the TCGA, we collected and pre-processed the data sets for four
cancer types (LUSC, GBM, KIRC and OV), including the clinical
records for each patient, and four types of high-throughput mo-
lecular data related to gene expression ((i) CNV; (ii) DNA methy-
lation; (iii) mRNA expression; (iv) miRNA expression, hereafter
denoted as diverse molecular features of a gene). An important
step in the process, described in Materials and Methods, was to
map each molecular feature to one or more genes, thereby
allowing us to examine subnetworks of interacting genes. For
each cancer type, we removed the samples with incomplete in-
formation for overall survival time or clinical variables (e.g. gen-
der, age, tumor stage and grade). We also eliminated genes with
low expression in all tumor types [22]. The information on the
final number of molecular features and samples used in down-
stream analysis is listed in Table 1.
The significance of each molecular feature correlated with
patient overall survival time was measured based on a univari-
ate Cox proportional hazards model (likelihood ratio test
P < 0.05 as cutoff, Figure 1A). In particular, we confirmed the as-
sociation of diverse molecular features with the survival time of
patients using 121 clinically relevant genes [6] (13 genes were
excluded by low expression filtering), and showed that the con-
tribution of these genes to survival involved multi-layered regu-
latory mechanisms that may vary in different types of cancers
(Supplementary Figure S2). To further evaluate the contribution
of each gene, we derived a score that indicated the collaborative
effect of all its molecular features on patient survival (Figure 1A,
and Materials and Methods section). Genes with a score>0 were
identified as survival-related genes (genes with at least one of
the four molecular features associated with patient survival
time). Generally, mRNA expression and DNA methylation fea-
tures gave the most contribution to patient survival variation,
followed by CNV and miRNA features. In KIRC, 73% of genes
were associated with patient survival on multiple molecular
layers followed by LUSC (30%), GBM (21%) and OV (12%),
and well-studied genes (genes with more molecular features
tested) tended to have higher scores (Supplementary Table S1
and Supplementary Figure S3).
Generating multi-dimensional subnetwork atlas for the
prognosis of human cancer
The initial analysis examined association with patient survival
on a gene-by-gene basis. Although this approach can correctly
identify critical genes, it is also likely to produce false positives.
We hypothesized that more robust and predictive results could
be obtained by examining subnetworks of interacting genes.
Therefore, after each gene was assigned a score (heat), HotNet2
[22, 23] was used to discover the survival-related subnetworks
or network modules from a large PPI network obtained from
HPRD [19] (Figure 1B, Materials and Methods). As a result, 30
subnetworks with at least four connected survival-related genes
were identified for OV, 87 for LUSC, 134 for KIRC and 52 subnet-
works for GBM, respectively.
To assess the predictive power of these candidate multi-
dimensional subnetwork signatures, we performed Monte Carlo
cross-validations with 100 randomizations of training and test-
ing sample groups, and the median C-index across 100 random-
izations was calculated for each subnetwork (Figure 1C, see also
Materials and Methods). The nonparametric C-index is scaled
such that a C-index of 1 indicates perfect prediction accuracy,
whereas a C-index of 0.5 is equal to random guess. We observed
that >97% of the subnetworks of OV, KIRC and LUSC had a me-
dian C-index >0.5, but only 65% from GBM had C-indexes >0.5.
Furthermore, 100 survival-permuted data were used to test if
the subnetwork-derived models showed statistically significant
predictive power. At a P-value< 0.05 level, we finally deter-
mined 20 subnetworks in OV (O1–O20), 30 in LUSC (L1–L30), 98
in KIRC (K1–K98) and 7 subnetworks in GBM (G1–G7) as prognos-
tic biomarkers. These subnetworks were numbered from 1 to N
according to the predictive power in descending order
(Supplementary Figure S4).
To understand and characterize the biological roles of each
subnetwork biomarker underlying the complex clinical pheno-
type, we further performed functional enrichment analysis
based on the known pathways or functional categories using
Enrichr [25]. This analysis identified several pathways known to
be involved in cancer, such as DNA repair pathway (K71, O17)
[26, 27], the mTOR pathway (K84, L8) [28], Vesicle (Lysosome,
Golgi, ER) and cytoskeleton regulation (K23, K67, L21, L22, G6,
O15) [29–31], Notch signaling (K93, L15, O7), the VEGF signaling
pathway (L20, O18) [32] and DNA damage response (O8) [33]. In
addition, we identified less characterized but interesting sub-
networks, such as the dynactin-related subnetwork (O1) in OV,
the miRNA-regulated kinetocore subnetwork in KIRC (K1) and
the PDKs-regulated metabolism switch subnetwork in LUSC (L2)
(Figure 2, Supplementary Figure S5 and Supplementary Table
S2). The roles of those subnetworks in cancer are worth further
investigation.
Molecular insights from the top prognostic model
To further understand why the multi-dimensional subnetworks
identified above may be related to patient survival, we used the
top-ranked subnetworks in OV, LUSC and KIRC as examples
(Figure 2 highlighted in red), while more examples can be found
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Figure 2. Evaluation and characterization of the multi-dimensional subnetwork-derived prognostic models. (A–D) C-indexes of models trained from the multi-dimen-
sional molecular profiles of the subnetworks in KIRC (Ntotal¼169) (A), LUSC (Ntotal¼313) (B), OV (Ntotal¼ 398) (C), GBM (Ntotal¼156) (D). For each cancer type, during
each of the 100 times of random splitting, 80% of the total samples were used to train the model and the remaining of 20% were used as the test set for C-index calcula-
tions. (The whiskers mark the 25th and 75th quartiles, with the median in the center). The red dashed lines marked the C-index equivalent to a random guess (C-index-
¼0.5). Functional enrichment analysis was performed using Enrichr to characterize the biological role of each subnetwork biomarker based on the known pathways or
functional categories. See also Supplementary Figure S5.
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in Supplementary Figure S6. Our subnetwork signatures contain
important genes, interaction partners and regulation patterns
that offer potential insight into mechanisms associated with
tumor behavior. For each subnetwork, a consensus prognostic
model was built using features that were selected in the LASSO
Cox regression model at least five times across the 100 Monte
Carlo cross-validations (Figure 3A, B(a) and C (a)) (information
for all the prognostic models in Supplementary Table S3). To
demonstrate the usefulness of these models, we evenly divided
patients into high-risk and low-risk groups according to each
patient’s predicted risk score, and observed significant survival
differences between the two groups (Figure 3B(b) and C(b),
Materials and Methods). We also tested the performance of the
models against an independent sample set derived from an-
other TCGA-based study [6] (Figure 3B(c) and C(c)). The differ-
ence of the molecular profile between the two risk groups was
shown in the heatmap (Figure 3B(d) and C(d)).
Dynactin-related subnework in OV—O1
Overall, O1 is dominated by genes related to dynactin and its
interacting partners, which play key roles in cytoskeleton re-
organization and spindle assembly. The hazard ratio (HR) was
used to estimate the association of individual molecular fea-
tures with survival (better or worse), where an HR >1 repre-
sented a worse prognosis. For example, mRNA_APC had an HR
of 1.543 and mRNA_DCTN1 had an HR of 1.35, indicating that a
higher level of expression of these genes was associated with
shorter survival, while mRNA_CASP2 (HR: 0.626) indicated that
the higher level of expression was associated with longer sur-
vival. Likewise, higher level copy number of DCTN1
(CNV_DCTN1), APC (CNV_APC) and MAPRE1 (CNV_MAPRE1) was
associated with a worse prognosis and higher level of DNA
methylation at PGAM1 promoter (methy_PGAM1) was associ-
ated with longer survival.
Prior knowledge helps us to understand how these molecu-
lar features influence cell function and may affect survival in
cancer. DCTN1 is the largest subunit of the dynactin complex
that binds to microtubules and cytoplasmic dynein, which is
required for cellular structures and motor functions [34]. DCTN1
can be cleaved by caspases during apoptosis, possibly explain-
ing why CASP2 upregulation is linked to better survival. MAPRE1
is a binding partner of both DCTN1 and APC, which combine to-
gether to regulate microtubule polymerization, spindle dy-
namics and chromosome alignment [35–38]. Overexpression of
MAPRE1 has been found to occur in tumors and its oncogenic
role has been shown to promote the b-catenin/T-cell factor
pathway [39, 40]. Though the link between PGAM1 and DCTN1
has not yet been conclusively shown, PGAM1 provide a meta-
bolic advantage to promote tumor growth by coordinating gly-
colysis and biosynthesis [41]. Therefore, our prediction showed
that low presence of dynactin protein DCTN1 and its binding
partners, such as MAPRE1 (with APC) by low mRNA, low copy
number or high DNA methylation, and high CASP2 (cleave
DCTN1) were associated with low risk of relapse, which matched
well with previously reported roles in cancer progression
(Figure 3B and Table 2).
Pyruvate dehydrogenase-related subnetwork in LUSC—L2
Aerobic glycolysis over oxidative phosphorylation (the Warburg
effect) is a hallmark of metabolic reprogramming in cancer cells
[42]. We predict a group of genes that are critical to regulate this
metabolic switch: Pyruvate dehydrogenase (PDHs; oxidative
phosphorylation related genes to convert pyruvate to acetyl-
CoA for TCA cycle) and PDKs (aerobic glycolysis related genes to
inhibit PDHs by phosphorylation) [42]. For example,
mRNA_PDHA1 by lower miR-326 is predicted to link to better sur-
vival. MiR-326 has been shown to be a tumor suppressor in colo-
rectal cancer [43] and gastric cancer [44], and elevated miR-326
could down-regulate MRP-1 (multidrug resistance-associated
protein) and sensitize drug resistant cells to VP-16 and doxo-
rubicin treatment [45]. Moreover, we predicted that lower
mRNA_PDK4 targeted by higher miR-103-1 and miR-16-2 was also
linked to better survival, by which cancer-favored aerobic gly-
colysis would be inhibited and the tumorigenic role of PDK4 has
been demonstrated at least through activating CREB-mTORC1
signaling cascade [46]. As to why elevated higher PDK2 was pre-
dicted with better survival, it is probably because cancer cells
are responsive to PDK2 inhibitors such as dichloroacetate [47].
In contrast, PDPs promote PDH activity by dephosphorylation
and inhibition of Warburg effect [48], which agrees well with
our prediction that lower methy_PDP1 is linked to better prog-
nosis (Figure 3C and Table 2). Thus, our prediction agrees well
with the metabolic reprogramming theory
Kinetocore-related subnework in KIRC—K1
Another top ranking yet less characterized subnetwork (K1) in
KIRC was related to ‘sister chromatid Cohesion’, which is critical
to accurately segregate chromosomes throughout cell cycle [49].
Low levels of miR-149 and miR-16a, which target KNTC1 and
ZW10, respectively, were associated with better prognosis,
implying that these genes improve prognosis. Both KNTC1 and
ZW10 are mitotic checkpoint proteins binding to kinetocores,
and cells lacking these proteins fail to arrest in mitosis when
exposed to microtubule inhibitors [50]. Meanwhile, a clear pat-
tern of lower mRNA of DSN1, MIS12, NSL1, ZWILCH and higher
methy_ZWINT is associated with better prognosis. DSN1 (MIS13)
and NSL1 (MIS14) are components of MIS12 complex, an un-
stable complex that may restrict kinetochore assembly to spe-
cific chromosomal regions [49]. ZWINT is a ZW10 and MIS12
interacting protein, and ZWILCH is a component of KNTC1/ZW10
complex, both of which are able to bridge kinetochore proteins
[51, 52]. The recruitment of these proteins (i.e. KNTC1, ZW10,
ZWILCH, ZWINT1) to kinetochores can be affected by Aurora B
kinase activity, and CASC5 can promote Aurora B activity to
phosphorylate the outer kinetochore, serve as a scaffold for
kinetocore protein assembly and increase kinetochore–microtu-
bule dynamics [53, 54]. Although the roles of each protein in
this subnetwork have not been well-characterized in cancer,
the importance of the kinetocore in cancer has been attributed
to genomic instability and aneuploidy formation, which are
common features of tumors [55] (Supplementary Figure S6 and
Table 2).
Understanding and evaluating the clinical utility of the
subnetwork atlas
Above all, we identified the subnetworks within the compre-
hensive PPI network perturbed (or affected) by multiple genetic
and epigenetic events associated with survival and further gen-
erated prognostic models from these multi-dimensional sub-
networks. These subnetworks as a whole function as an atlas or
landmark for cancer prognosis and reflect the dys-regulation of
diverse cellular events underlying cancer outcome, including
cell cycle, cellular response to stress, metabolism, signal trans-
duction, gene expression, developmental biology, metabolism
of protein, DNA repair and replication and others, thus provid-
ing clues about which cellular functions and biochemical path-
ways contribute to cancer outcome (Figure 4A).
1050 | Zhang et al.
Figure 3. Top-ranked subnetwork biomarkers in OV and LUSC as examples to illustrate the molecular insights from the prognostic models. (A) Selection procedure for
the important molecular features used to build the prognostic model for each subnetwork. (B and C) (a) Frequency of the molecular features selected by LASSO during
the 100 samplings of training data; (b) Kaplan–Meier analysis according to the subnetwork-derived prognostic model, comparing overall survival time for predicted
higher-risk patients versus lower-risk patients. The differences between the two curves were determined by the two-sided log-rank test; (c) Kaplan–Meier estimates of
overall survival in independent test data sets. The differences between the two curves were determined by the two-sided log-rank test; (d) The heatmap of the molecu-
lar profile for the subnetwork biomarker: Rows represent patients (grouped as higher-risk or lower-risk), and columns represent selected molecular features used for
making predictions. Z-score transformation was used to adjust the data scale among different molecular data sets when generating heatmaps. See also
Supplementary Figure S6.
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We further annotated the subnetworks using Drugbank
(http://www.drugbank.ca) and the cancer gene index (CGI,
https://wiki.nci.nih.gov/display/cageneindex) gene-compound
database to identify genes that have Food and Drug
Administration (FDA)-approved drugs or experimental com-
pounds available (Figure 4A genes labeled as red and yellow, re-
spectively). We captured 35 (22.6%) subnetworks (KIRC:26,
LUSC:3, OV:5, GBM:1) with FDA-approved drugs available, such
as VEGF-related subnetwork (L20), proteasome-related subnet-
work (K64) and cholesterol synthesis/sterol response-related
subnetwork (K40) that are well-known to be related to cancer.
Moreover, we also identified 123 (79.3%) subnetworks (KIRC:79,
LUSC:22, OV:18, GBM:4) with available experimental com-
pounds, such as those related to kinetochore (K72), Notch sig-
naling (L15) and dynactin (O1), that are currently being
scrutinized as targets in cancer studies. There are also a number
of subnetworks (KIRC:17, LUSC:7, OV:2, GBM:2) without any
compound available, whose roles in cancer have been either in-
tensively (i.e. G7) or barely characterized (i.e. O5, K87) (Figure
4A, highlighted in box, and Supplementary Figure S5).
We also compared the predictive power between using
standard clinical variables alone and in combination with our
multi-dimensional subnetwork biomarkers. Improved predict-
ive power was shown in 22 subnetwork models in KIRC (one-
sided Wilcoxon signed rank test, P < 0.03, fdr< 0.05). However,
the quantitative gains (in terms of the median value of Somers’
D rank correlation coefficient across the 100 splits, Somers’ D
equals to 2*C-1 where C denotes C-index) were limited (2.1–
14.4% for 22 subnetwork-based models). Improved predictive
power was also observed for all 30 subnetwork models in LUSC
(one-sided Wilcoxon signed rank test, P < 0.007, fdr< 0.001)
with apparent gains (Somers’ D, 36.4–132%) (Figure 4B and
Supplementary Table S2). As shown in Figure 4B, if the 313 pa-
tients with LUSC were stratified based on clinical variables (age
and tumor stage), there was no clearly difference in median sur-
vival time (high-risk group: 55 months versus low-risk group: 64
months, log-rank P ¼ 0.3020). In contrast, combing the subnet-
work biomarker L4, as an example, we observed that the low-
risk group had a median survival of 108 months, whereas the
high-risk group had a median survival of 33 months (log-rank
P < 0.0001). Additionally, the top two in GBM (G1, related to
cytokine production; G2, containing RB-related genes) and one
in OV (O3) showed improved prediction. Thus, the addition of
our subnetwork models could facilitate traditional cancer man-
agement merely based on clinical variables.
To further facilitate clinical application, we narrowed down
the enormous genome-wide molecular features into a smaller
set of key subnetworks associated with survival and provided
the ranking of the most important molecular features, which
won out from our stepwise analysis in Supplementary Table S3.
In addition, we developed a freely accessible web-based re-
source of our results to allow researchers in basic science and
translational medicine to use the prognostic models directly to
uncover specific genes or markers of interest, and avoid the
time-consuming genome-wide screening. The homepage of the
resources can be accessed via http://fanlabresources.org/.
Identifying tumor subtypes associated with patient
survival
We further assessed if our subnetwork atlas could help to stratify
patients into distinct clusters or subtypes that were associated
with survival. In all, 169 KIRC patients were divided into three
clusters via non-negative matrix factorization (NMF) based on the
similarity of their molecular profiles, which included 897 molecu-
lar features (CNV: 186, methylation: 163, mRNA: 425, miRNA: 123)
derived from the 98 subnetwork models (Figure 5A). The three
subtypes of patients were predicted consistently as low-,
Table 2. Important molecular features identified from the top-performing and less characterized multi-dimensional subnetwork-derived prog-
nostic models
Subnet Molecular features HR 95% CI of HR P value
O1 mRNA_CASP2 0.626 0.478–0.82 0.00068
Dynactin-microtubule-related
sub-network
CNV_DCTN1 1.738 1.226–2.463 0.00189
CNV_APC 1.4495 1.0555–1.99 0.0218
Methy_ PGAM1 4.35E-05 6.14E-09–0.31 0.0264
mRNA_APC 1.543 1.051–2.264 0.0268
CNV_MAPRE1 1.2386 1.022–1.5 0.0292
mRNA_DCTN1 1.3482 1.0116–1.7967 0.04145
L2 hsa.mir.326 1.29 1.11–1.5 0.00092
Regulation of pyruvate dehydrogenase
(PDH) complex related sub-network
methy_PDP1 1.79Eþ10 10395–3.08Eþ16 0.00127
hsa.mir.16.2 0.7156 0.5648–0.9067 0.00558
CNV_PDK2 0.3744 0.185–0.7573 0.0063
mRNA_PDK4 1.1225 1.0228–1.232 0.015
hsa.mir.103.1 0.6958 0.5145–0.94 0.0185
K1 hsa.mir.149 1.6438 1.3039–2.0723 2.6E-05
Resolution of sister chromatid
cohesion-related sub-network
methy_ZWINT 6.29E-101 1.95E-154–2.03E-47 2.42E-04
CNV_ZWILCH 0.031 0.0037–0.2534 0.00122
hsa.mir.18a 1.9256 1.2915–2.871 0.0013
hsa.mir.192 0.778 0.66–0.9124 0.002
CNV_CASC5 0.109 0.0266–0.4467 0.002
mRNA_ZWILCH 2.335 1.2446–4.382 0.0083
mRNA_ZWINT 1.782 1.1267–2.8179 0.0135
mRNA_KNTC1 1.6255 1.0743–2.4596 0.0215
mRNA_DSN1 2.11 1.0668–4.169 0.03188
HR ¼ hazard ratio, CI ¼ confidence interval, two-sided P values were derived from the univariate cox proportional hazards model.
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Figure 4. Clinical utility of the subnetwork-based prognostic biomarkers. (A) The subnetwork biomarkers from four cancer types were grouped into multiple cellular
events based on Reactome database annotation, including cell cycle (green), cellular response to stress (brown), metabolism (orange), signal transduction (blue), gene
expression (cognac), developmental biology (light purple), metabolism of protein (rouge), DNA repair and replication (purple) and others (yellow), represented by nine
pie slices. Inside each pie slice, subnetworks from each cancer type were plotted (Blue: LUSC; Green: KIRC; Orange: OV; Purple: GBM), and the length of branch is re-
versely correlated to enrichment analysis P-value (longer distance, more significant). Genes annotated to each functional category were shown with a larger font size.
Genes were also annotated using Drugbank (http://www.drugbank.ca) and the CGI (https://wiki.nci.nih.gov/display/cageneindex) gene-compound database. The genes
targeted by FDA-approved drugs or with experimental compounds available in cancer studies were labeled red and yellow, respectively. Unlabeled genes have not yet
been clearly targeted. The enriched Reactome pathway and significant P-value for each subnetwork were shown in the bar chart on the right panel. The bar height cor-
responds to the enrichment P-value. All subnetworks were highly enriched in Reactome pathways with P-values ranging from 10E-4 to 10E-18. (B) C-indexes by models
trained from clinical variables alone or in combination with each subnetwork biomarker in KIRC (Ntotal¼169) and LUSC (Ntotal¼313). The black dotted line highlights
the integrated models of subnetwork molecular data and clinical variables (red) that show better performance than that based on clinical variables alone (yellow). (The
whiskers mark the 25th and 75th quartiles, with the median in the center). See also Supplementary Figure S5.
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moderate- and high-risk by most of the subnetwork-derived
prognostic models and showed distinct survival patterns (Figure
5B and C). Meanwhile, k-means clustering (KMC) algorithm was
used to find the molecular subtypes of the KIRC patients, which
yielded similar stratification of patients (Figure 5D). Likewise, 351
molecular features (CNV: 95, methylation: 88, mRNA: 122, miRNA:
46) derived from the 30 subnetworks were used to discover
molecular subtypes of 313 LUSC patients that showed different
survival patterns (Figure 5E).
Independent validation of the subnetwork-derived
prognostic models
According to the work of Tibishirani and Efron [56], our models
might fit more to the data set that we used to train and generate
Figure 5. Survival-related tumor stratification in KIRC and LUSC. (A) Three molecular subtypes (clusters) were revealed by consensus non- NMF clustering of 169 KIRC
patients based on 897 molecular features (CNV: 186, methylation: 163, mRNA: 425, miRNA: 123) derived from the 98 subnetwork-based prognostic models reveals three
molecular subtypes (clusters). (B) The three subtypes of patients were predicted consistently as low-, moderate- and high-risk by most of the subnetwork-derived prog-
nostic models. (C and D) Kaplan–Meier curves of overall survival for the three clusters of KIRC patients, identified by NMF or KMC. (E) Kaplan–Meier curves of overall
survival for three clustered LUSC patients identified by NMF or KMC based on 351 molecular features (CNV: 95, methylation: 88, mRNA: 122, miRNA: 46) derived from 30
subnetwork models.
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the models. We think one way to solve this problem is to valid-
ate these models using completely independent data sets.
Given the limited availability of suitable independent data pro-
viding the highly integrated multi-dimensional genomic data,
we evaluated the performance of the prognostic models ob-
tained from LUSC or KIRC using two independent data sets—
Lung Adenocarcinoma (LUAD) or Kidney renal papillary cell car-
cinoma (KIRP) from TCGA, which are two histological distinct
lung or kidney cancer, respectively. We got 414 samples from
LUAD and 233 samples from KIRP with complete patient sur-
vival information and all four types of molecular data that were
generated by the same platform as in LUSC or KIRC. We found
that 27 of 30 (90%) prognostic models in LUSC were confirmed in
LUAD (log-rank P-values ranging from 0.0495 to 3.15E-08) and 83
of 98 (85%) prognostic models in KIRC were confirmed in KIRP
(log-rank P-values ranging from 0.0463 to 1.31E-06) (Figure 6A
and B). Furthermore, we did another independent validation
using the data set from a recently published International
Cancer Genome Consortium (ICGC) ovarian cancer project [57],
where we got 107 samples from the Australia OV cancer study
with complete patient survival information and all four types of
molecular data. We found that 17 of the top 20 models trained
from TCGA OV were validated in the ICGC Australia OV data set
(log-rank P-values ranging from 0.0434 to 1.38E-06) (Figure 6C).
In addition, considering the fact that in regular clinical practice
physicians may not be able to make all of these measurements
for every patient as the TCGA has done, we further analyzed
which type of molecular feature was the most informative. We
counted the frequency of each type of the four molecular fea-
tures, which were selected by LASSOþCox when building the
prognostic models, and observed that the mRNA feature got the
highest selection probability in all four cancer types
(Supplementary Figure S9A). Therefore, we further tested if
using mRNA features alone in our subnetwork models could
also predict patient survival. We found that 66 models (67%) in
KIRC and 20 models (67%) in LUSC could also effectively predict
patient survival in KIRP and LUAD, respectively (log-rank P-
value< 0.05, Supplementary Figure S9B), though the combined
feature set gave better performance.
Discussion
In contrast to previous studies driven by a single molecular data
type or assumptions that genes act independently, in this study,
we focused on the potential impact of multiple genetic and epi-
genetic (gene expression, CNV, miRNA expression and DNA
methylation) changes on the molecular states of networks that
in turn affects complex cancer outcome. Here we report our
methodology to generate a multi-dimensional subnetwork atlas
for cancer prognosis through integrating cancer genomic and
interactome data. Through this approach, we uncovered an
average of 38 subnetwork-derived prognosis biomarkers in four
cancer types. The subnetworks identified are involved in many
pathways associated with cancer prognosis and include several
promising targets for precision cancer therapy. Interestingly, a
number of subnetworks with less characterized roles in cancer
stood out, thus providing extra clues to the biological pathways
that may contribute to cancer outcome. The integrative analysis
not only explores the gene–gene relations but also helps to bet-
ter understand how multiple regulatory mechanisms are orch-
estrated together to affect cancer survivorship and narrow
down the enormous molecular features into a smaller set of key
subnetworks (modules) associated with survival.
Subnetwork signatures provide potential strategies for clin-
ical cancer treatment. By annotating genes with FDA-approved
drugs or experimental compounds (Figure 4A and
Supplementary Figure S5), we not only demonstrate that our
subnetworks contain drug targets but also provides new in-
sights into previously underestimated factors that may be cru-
cial in cancer prognosis, such as VEGF-related subnetwork (L20),
a well-studied cancer-related signaling pathway that promotes
angiogenesis [58], However, anti-VEGF monotherapy (mainly
anti-VEGFA) is not as efficient as conventional chemotherapy,
and the survival beneficial effect comes when combining anti-
VEGF with cytotoxic agents for patients with particular cancer
subtypes [59]. Our prediction reinforces the previously underes-
timated signaling mediated by VEFGB and PGF (placental growth
factor), whose receptors are FLT1 (VEGFR-1) and neuropilin NRPs
(not VEGFR-2), with no obvious role in angiogenesis but import-
ant in altering cytokine release and immune cell chemotaxis
[58]. We also captured a number of subnetworks without any
compound available, whose roles in cancer are either inten-
sively (i.e. G7) or barely characterized (i.e. O5, K87). G7 is an
autophagy-related subnetwork with paradoxical effects: either
as a tumor suppressor or inducer of apoptosis (i.e. ATG6/Beclin1)
or a pro-survival signal to protect tumor from metabolic stress
particularly induced by chemo/radio therapy [60]. Here, we pre-
dict that high CNV and mRNA of GABARAPL2 (ATG8) and high
CNV_ATG5 are associated with better survival, while high CNV_
ULK1 (ATG1) and high methylation at ATG3/10/12 are associated
with worse prognosis, providing a potential guideline to select-
ively activate or inhibit individual autophagy-related proteins
using small molecules or antibodies. In contrast, O5 and K87 are
barely studied. O5 mainly contained small nuclear ribonucleo
proteins (SNRPs), components of the spliceosome complex to
process pre-mRNA to its mature and functional form [61].
Interestingly, WDR77 in O5 may function as a final target of
SNRPs, which has been shown to stimulate ovarian cancer cell
proliferation [62]. Similarly, K87 contained various RNA poly-
merase I (Pol I) and their associated factors, such as RRN3 and
CD3EAP, which can interact with TAF and play important roles
in Pol I recruitment [63, 64]. CD3EAP’s effect in prognosis has
also been linked to NF-jB activity in myeloma patients [65].
Moreover, several subnetworks with experimental compounds
available are targets currently being investigated in cancer
studies, such as K1/80/72 and L15. K1/80/72 are three
kinetochore-relate subworks: K80 contains CENPE/CENPF, which
are centromere proteins; K1 contains kinetochore-associated
proteins including RZZ (ROD, ZW10, ZWILCH) complex and
MIS12 (MIS12, DSN1, NSL1) complex, which are crucial for kin-
etochore assembly and microtubule interactions; and K72 con-
tains conserved microtubule binding protein CLIP and
associating protein CLASP, which can promote the growth of
kinetochore-bound microtubules [49]. Thus, our prediction
agrees well with the understanding that kinetochore regulation
and higher order chromatin structure play important roles in
cancer [22]. L15 is a Notch signaling-related network. Elevated
NOTCH1 and its ligand JAG1 have been detected and linked to
poor prognosis in breast cancer [66] and using c-secretase in-
hibitors to block Notch1 signaling may sensitize colon cancer to
chemotherapy [67]. In conclusion, our subnetwork signatures
provide possibilities to identify drug targets and guidelines of
how to modulate functions of the identified subnetworks.
The multi-dimensional subnetwork biomarkers could ad-
vance the predictive power of cancer prognosis. Among the four
cancer types, using the clinical-variables alone showed substan-
tial predictive power for three cancers (OV, KIRC, GBM), with
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median C-indexes significantly >0.5 (0.629–0.783), comparable
with a previously published result [6], despite that the samples
we used are slightly different (<30% different samples were
used). However, in combination with our subnetwork bio-
markers, the quantitative gains were limited in KIRC (Somers’
D, 2.1–14.4% for 22 subnetwork-based models in KIRC; a 2.1%
gain in Somers’ D corresponds to a 2.1% increase of rank correl-
ation coefficient between predicted risk score and observed sur-
vival time), suggesting largely redundant information between
clinical variables and molecular data in terms of patient sur-
vival stratification as discussed in previous study [6]. In con-
trast, though using clinical variables alone yielded poor
prediction with a C-index of only 0.4917 for our 313 core LUSC
samples, addition of molecular data provided crucial
complementary information and significant gains in predictive
power (Somers’ D, 36.4–132%). This indicates that the predictive
power of the clinical variables may partly depend on the data
quality, such as patient population and tumor type. Therefore,
clinical variables and multiple types of molecular data may pro-
vide crucial complementary information to achieve more robust
predictive power when building prognostic models (Figure 4B).
Meanwhile, we would like to point out the importance of the
data quality and the choice of parameter cutoff. First, the in-
completeness of interactome data and some other protein inter-
action types (i.e. genetic) or the predicted miRNA–mRNA
interactions not used in this study might limit our findings of
subnetwork signals. Second, in the procedure of genome-wide
screening of all potential molecular features that may correlate
Figure 6. Independent validation of the prognostic models obtained from LUSC, KIRC or OV. (A) 83 of 98 (85%) subnetwork-derived prognostic models in KIRC were also
significant predictors of patient survival in KIRP based on log-rank test (blue points). Kaplan–Meier survival plots for the top two prognostic models for 233 KIRP pa-
tients were shown. (B) 27 of 30 (90%) subnetwork-derived prognostic models in LUSC were also significant predictors of patient survival in LUAD (blue points). Kaplan–
Meier survival plots for the top two prognostic models for 414 LUAD patients were shown. (C) 17 of the top 20 (85%) prognostic models trained from TCGA OV were also
validated using ICGC Australia OV cancer data set (blue points). Kaplan–Meier survival plots for the top three prognostic models for 107 ICGC Australia OV patients
were shown.
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with patient survival, we used a less stringent cutoff P< 0.05
(likelihood ratio test) to keep more information. When testing a
more stringent cutoff P< 0.01, a multiple comparison adjust-
ment P-value cutoff (fdr<0.05) or an additional combined P-
value based on Fisher’s method (combined P< 0.05) in KIRC and
LUSC, we found that most robust networks continued to be
identified (Supplementary Figure S7). On the other hand, when
using a more stringent cutoff, some survival-related subnet-
works were lost, such as K17 (CST, KLRK1, MICA, MICB) related
to natural killer cell-mediated cytotoxicity pathway (using P< 0.
01) and L15 (JAG1, MFNG, NOTCH2, POFUT1) related to NOTCH
signaling pathway (using fdr< 0.05).
Additionally, it should be noted that though our study pro-
vides important insights of translating molecular data into clin-
ical utility, it still has some limitations that could provide
guidance for future work. First, current gene scoring method
treated the molecular features of individual gene as independ-
ent and had a bias toward well-studied genes (genes with more
molecular features tested) (Supplementary Figure S3). Second,
though LASSO was good for selecting most important features
to overcome the over-fitting problem and make a fair evaluation
to different subnetworks (with different number of genes), it
would lose some equally important features when high pair-
wise correlations occurred. Though our subnetworks were
exacted from physical PPI network and overall weak correl-
ations were observed among the majority of interacting genes
(Supplementary Figure S8), the potential intrinsic relations
among biologically relevant genes will lead to some level of cor-
relations. In future study, more effective gene scoring method
and feature selection strategies should be applied, such as elas-
tic net [68], which combines penalty terms of LASSO and Ridge,
to compromise between variable selection and group effect.
In conclusion, here we reported our three-step approach to
build a multi-dimensional subnetwork atlas or landmark for
cancer prognosis by integrating cancer genomics and interac-
tome data, represented as PPI modules perturbed by multiple
genetic and epigenetic events that correspond to patient sur-
vival. Besides narrowing down the enormous genome-wide mo-
lecular features into a smaller set of key subnetworks
associated with survival, we also provided the ranking of the
most important molecular features and developed a freely ac-
cessible web-based resource of our results to allow researchers
in basic science and translational medicine to use the prognos-
tic models directly to uncover specific genes or markers of inter-
est, and avoid the time-consuming genome-wide screening.
Therefore, our study provides a new analytical tool to systemat-
ically dissect the comprehensive infrastructures that guide pa-
tient outcomes and a new paradigm of how genomic data can
be used to better inform clinicians for advancing cancer care
management.
Key Points
• We proposed an integrative systems biology approach
to build an atlas or landmark for cancer prognosis.
• We identified the subnetworks within the comprehen-
sive PPI network perturbed (or affected) by multiple
genetic and epigenetic events associated with survival
and further generated prognostic models from these
multi-dimensional subnetworks.
• The clinical utility of the multi-dimensional subnet-
work atlas was evaluated by prognostic impact evalu-
ation, functional enrichment analysis, drug target
annotation, tumor stratification and independent
validation.
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Supplementary data are available online at https://academic
.oup.com/bib.
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